This trial is active, not recruiting.

Condition prostate cancer
Treatments radiotherapy 70 gy, radiotherapy 76 gy, androgen blockade
Phase phase 3
Sponsor Abdenour Nabid
Collaborator AstraZeneca
Start date December 2000
End date January 2018
Trial size 600 participants
Trial identifier NCT00223145, DC-990-0049, DC-990-0049,1


The hypothesis of the proposed study would be that, due to the six months of total androgen blockade, which would include neoadjuvant hormonal therapy for four months and concomitant hormonal therapy for two months with irradiation, the investigators could reduce local failure rates for these two dosage levels, namely 70 Gy and 76 Gy. Since increasing the dose to the prostate also seems to reduce local relapse rates, the results of the two hormonal therapy groups would be compared with the results of prostate irradiation at doses of 76 Gy. This study would verify the possibility of compensating a six Gy dosage increase of radiation therapy with six months of hormonal therapy between the 70 Gy and 76 Gy groups who received hormonal therapy, and also match these results with a dose escalation to the prostate of 76 Gy. In the future, this could result in more therapeutic choices, such as reducing the doses of radiation therapy and, consequently, its related complications, if hormonal therapy proves to be beneficial; or rather, to continue in the direction of dose escalation for this intermediate-risk patient group, everything being correlated to the side effects of hormonal therapy and irradiation.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Androgen blockade for 6 months + Radiotherapy 70 Gy
radiotherapy 70 gy
Radiotherapy to the prostate
androgen blockade Bicalutamide 50 mg
Duration : 6 months
Androgen blockade for 6 months + Radiotherapy 76 Gy
radiotherapy 76 gy
Radiotherapy to the prostate
androgen blockade Bicalutamide 50 mg
Duration : 6 months
(Active Comparator)
Radiotherapy alone with 76 Gy
radiotherapy 76 gy
Radiotherapy to the prostate

Primary Outcomes

Interval before biochemical failure
time frame: 10 years
Disease-free survival
time frame: 10 years

Secondary Outcomes

time frame: 10 years
time frame: 10 years

Eligibility Criteria

Male participants from 18 years up to 80 years old.

Inclusion Criteria: - Patients with stage T1 or T2 untreated adenocarcinoma of the prostate, with a Gleason score that is less than or equal to 6, as well as a prostate-specific antigen (PSA) between 10-20 (intermediate risk) or patients with stage T1 or T2 untreated adenocarcinoma of the prostate, with a Gleason score that is equal to 7, as well as a PSA equal to or less than 20 (intermediate risk). - Performance status score of 0-1 - Patients must sign a consent form before starting the study. - No evidence of regional disease - Patients with a previous history of cancer are eligible on the condition that they have been disease-free for more than five years. - Non-invasive epidermoid cancers of the skin are eligible. - The patient must be available for treatments and follow-up visits. - No evidence of metastatic disease, confirmed by a negative bone scan. Exclusion Criteria: - Severe medical or psychiatric problems that may compromise study compliance - Chronic hepatic disease; abnormal hepatic function, i.e. aspartate aminotransferase and alanine aminotransferase > 1.5 times the upper normal limit.

Additional Information

Official title Randomized, Multicentre, Phase III Study in Patients With Intermediate-risk T1 T2 Prostate Adenocarcinomas, to Verify the Role of Six Months of Total Androgen Blockade for Two Dosage Levels of Prostate Radiation Therapy (70 Gy and 76 Gy) Versus Prostate Radiation Therapy Alone at 76 Gy
Principal investigator Abdenour Nabid, MD
Trial information was received from ClinicalTrials.gov and was last updated in July 2013.
Information provided to ClinicalTrials.gov by Université de Sherbrooke.